// App-Quantinova.ai

OP0237 (2018) : A comparison of pk and pd outcomes of tocilizumab in giant cell arteritis after sc and iv dosing

Researchers

Presenter

  • N.L. Mallalieu

Principal Investigators

  • J.H. Stone

  • P. Villiger

  • M. Klearman

  • L. Brockwell

  • S. Dimonaco

  • J.E. Charion

Medical Centers

  • Roche Innovation Center, New York, NY

  • Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

  • inselspital, Rheumatology, Immunology and Allergology, Bern, Switzerland

  • Genentech, Inc., South San Francisico, CA

  • Roche Products Limited, Welwyn Garden City

  • Roche Innovation Center Basel, Basel, Switzerland

Locations

  • United States

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Cardiovascular (CVS)

Disease

  • Giant cell arteritis

Biomarkers

  • C reactive protein

  • Estrogen receptor alpha

  • Interleukin 6

Drug/Treatment

  • Tocilizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved